Invest New Drugs 2020 Feb 01
Metabolomic profiling to evaluate the efficacy of proxalutamide, a novel androgen receptor antagonist, in prostate cancer cells.
Qu F, Gu Y, Wang Q, He M, Zhou F, Sun J, Wang G, Peng Y
Proxalutamide is a newly developed androgen receptor (AR) antagonist for the treatment of castration-resistant prostate cancer (PCa) that has entered ...
Read More
Source: PubMed
Med Lett Drugs Ther
Darolutamide (Nubeqa) for prostate cancer.
Read More
Source: PubMed
Pharmacol Rep
Dietary lipids and environmental xenobiotics as risk factors for prostate cancer: The role of cytochrome P450.
Maksymchuk O, Kashuba V
Prostate cancer is one of the most common malignant neoplasms in men. Because of the increase in the number of cases as well as development of cancers ...
Read More
Source: PubMed
Osteoporos Int 2020 Jan 28
A randomized, open-label, controlled trial of monthly oral minodronate or semiannual subcutaneous injection of denosumab for bone loss by androgen deprivation in Asian men with prostate cancer: the PRevention of Osteopenia with Minodronate And DEnosumab (PROMADE) study.
Yoshida T, Kinoshita H, Taniguchi H, Yanishi M, Sugi M, Matsuda T
There is still a lack of evidence that minodronate or denosumab prevents bone loss due to androgen deprivation therapy (ADT) in non-Western patients. ...
Read More
Source: PubMed
Cell Death Dis
The transcription elongation factor TCEA3 induces apoptosis in rhabdomyosarcoma.
Kazim N, Adhikari A, Oh TJ, Davie J
TCEA3 is one of three genes representing the transcription elongation factor TFIIS family in vertebrates. TCEA3 is upregulated during skeletal muscle ...
Read More
Source: PubMed
